Aberrant signaling through the HGF/MET pathway has clinically been linked to oncogenic potential and poor outcomes in NSCLC, with shortened overall survival (OS) and progression-free survival (PFS). The gene discussed is HGF; the disease is non-small cell lung carcinoma.